Edition:
United Kingdom

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

23.84USD
11 Dec 2018
Change (% chg)

-- (--)
Prev Close
$23.84
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
610,278
52-wk High
$23.94
52-wk Low
$2.86

Latest Key Developments (Source: Significant Developments)

Endocyte Announces FDA Acceptance Of Radiographic Progression Free Survival As An Alternative Primary Endpoint Of The Vision Trial In Addition To Overall Survival
Monday, 10 Sep 2018 

Sept 10 (Reuters) - Endocyte Inc ::ENDOCYTE ANNOUNCES FDA ACCEPTANCE OF RADIOGRAPHIC PROGRESSION FREE SURVIVAL (RPFS) AS AN ALTERNATIVE PRIMARY ENDPOINT OF THE VISION TRIAL IN ADDITION TO OVERALL SURVIVAL (OS).UNDER UPDATED PROTOCOL, NOW EXPECT ANALYSIS OF RPFS FOR POTENTIAL FULL APPROVAL TO OCCUR BEFORE END OF 2019.OTHER ASPECTS OF VISION TRIAL, INCLUDING PATIENT TREATMENT & ASSESSMENTS, TRIAL SIZE, OVERALL DURATION, & FOLLOW UP REMAIN UNCHANGED.ACCEPTANCE OF RPFS AS A PRIMARY ENDPOINT FOR FULL APPROVAL IN EUROPE WILL BE DETERMINED IN UPCOMING REGULATORY INTERACTIONS.FINAL OS ANALYSIS OF VISION TRIAL EXPECTED TO OCCUR NEAR END OF 2020.RPFS IS APPROPRIATE EFFICACY ENDPOINT IN ONGOING PHASE 3 VISION TRIAL TO SUPPORT NDA SUBMISSION FOR FULL FDA APPROVAL OF (177)LU-PSMA-617.  Full Article

Endocyte Q2 Loss Per Share $0.17
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Endocyte Inc ::Q2 LOSS PER SHARE $0.17.Q2 EARNINGS PER SHARE VIEW $-0.17 -- THOMSON REUTERS I/B/E/S.IND FILING FOR EC17/CAR T-CELL THERAPY ON TRACK FOR Q4 2018.CASH, CASH EQUIVALENTS, INVESTMENTS $166.8 MILLION AT JUNE 30, 2018, VERSUS $118.4 MILLION AT JUNE 30, 2017.ANTICIPATES ITS CASH, CASH EQUIVALENTS AND INVESTMENTS BALANCE AT END OF 2018 TO EXCEED $130 MILLION.ENDOCYTE - HAS SUFFICIENT CASH TO FUND ACTIVITIES THROUGH EXPECTED END OF VISION TRIAL & POTENTIAL PROOF OF CONCEPT OF EC17/CAR T-CELL THERAPY.  Full Article

Endocyte And ITM Announce Long-Term Supply Agreement For No-Carrier-Added Lutetium-177
Monday, 9 Jul 2018 

July 9 (Reuters) - Endocyte Inc ::ENDOCYTE AND ITM ANNOUNCE LONG-TERM SUPPLY AGREEMENT FOR NO-CARRIER-ADDED LUTETIUM-177.ENDOCYTE - ADDITIONAL TERMS OF THE AGREEMENT ARE NOT DISCLOSED.ENDOCYTE - ITG WILL PROVIDE ENDOCYTE WITH 100% OF LUTETIUM-177 REQUIRED FOR THE PHASE 3 VISION TRIAL.ENDOCYTE - CO WILL PAY €5 MILLION UP-FRONT TO SUPPORT EXPANSION OF MANUFACTURING CAPACITY FOR LUTETIUM-177.  Full Article

‍Partner Fund Management LP reports a 6.6 pct passive stake in Endocyte as of Nov 6
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Endocyte Inc :‍Partner Fund Management LP reports a 6.6 percent passive stake in Endocyte Inc as of November 6 - SEC Filing​.  Full Article

Endocyte Q3 loss per share $0.55
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Endocyte Inc :Endocyte reports third quarter financial results.Q3 loss per share $0.55.  Full Article

Endocyte Inc files for mixed shelf of upto $150 million
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Endocyte Inc ::Endocyte Inc files for mixed shelf of upto $150 million .Endocyte Inc says in addition, selling stockholders may offer and sell, up to 5.3 million shares of co's common stock‍​.  Full Article

Peter Dodwell reports 7.1 pct passive stake in Endocyte Inc
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Endocyte Inc :Peter Dodwell reports 7.1 percent passive stake in Endocyte Inc ‍​as of September 29 - SEC filing.  Full Article

  • Previous
  • Next

Endocyte Inc News

BRIEF-Endocyte - On Nov 30, Waiting Period With Respect To Filing Under Hart-Scott-Rodino Act Expired In Connection With Proposed Merger With Novartis AG

* ENDOCYTE SAYS ON NOV 30, 2018, WAITING PERIOD WITH RESPECT TO FILING UNDER HART-SCOTT-RODINO ACT EXPIRED IN CONNECTION WITH PROPOSED MERGER WITH NOVARTIS AG Source text: [https://bit.ly/2SogDFh] Further company coverage:

» More ECYT.OQ News

Earnings vs. Estimates

» More Financials